Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of SCLC, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Pyxis Oncology, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

 PHASE 1 MONOTHERAPY EXPANSION STUDY OF MICVOTABART PELIDOTIN (MICVO) FOR RECURRENT AND METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA (R/M HNSCC) PATIENTS PROGRESSING WELL WITH PRELIMINARY DATA IN SECOND HALF OF 2025 AND FIRST HALF OF 2026

PYXIS ONCOLOGY REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BOSTON, JUNE 30, 2025 (GLOBE NEWSWIRE) -- PYXIS ONCOLOGY, INC. (NASDAQ: PYXS), A CLINICAL-STAGE COMPANY DEVELOPING NEXT-GENERATION ANTIBODY-DRUG CONJUGATE (ADC') THERAPEUTICS FOR DIFFICULT-TO-TREAT CANCERS, REPORTED TODAY THAT PYXIS ONCOLOGY'S COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS GRANTED STOCK OPTIONS TO PURCHASE AN AGGREGATE OF 246,238 SHARES OF PYXIS ONCOLOGY'S COMMON STOCK TO FOUR NEWLY HIRED EMPLOYEES. THE AWARDS WERE GRANTED UNDER THE PYXIS ONCOLOGY, INC. 2022 INDUCEMENT PLAN (THE PLAN') WITH A GRANT DATE OF JUNE 30, 2025, AS AN INDUCEMENT MATERIAL TO THE NEW EMPLOYEE ENTERING EMPLOYMENT WITH PYXIS ONCOLOGY, IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

PYXIS ONCOLOGY REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

- ANNOUNCED ROBUST PRECLINICAL DATA SUPPORTING THE UNIQUE THREE-PRONGED MECHANISM OF ACTION OF MICVOTABART PELIDOTIN (MICVO, FORMERLY PYX-201), DRIVING ANTI-TUMOR ACTIVITY VIA DIRECT TUMOR KILLING, BYSTANDER EFFECT AND IMMUNOGENIC CELL DEATH

PYXIS ONCOLOGY REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BOSTON, MAY 14, 2025 (GLOBE NEWSWIRE) -- PYXIS ONCOLOGY, INC. (NASDAQ: PYXS), A CLINICAL-STAGE COMPANY DEVELOPING NEXT-GENERATION ADC THERAPEUTICS FOR DIFFICULT-TO-TREAT CANCERS, TODAY ANNOUNCED THAT LARA S. SULLIVAN, M.D., PRESIDENT, CHIEF EXECUTIVE OFFICER AND CHIEF MEDICAL OFFICER, WILL PARTICIPATE IN FIRESIDE CHATS AND BE AVAILABLE FOR ONE-ON-ONE MEETINGS WITH INVESTORS AT THE FOLLOWING TWO UPCOMING INVESTOR CONFERENCES.

PYXIS ONCOLOGY TO PARTICIPATE IN TWO UPCOMING INVESTOR CONFERENCES

GENE SIGNATURES ASSOCIATED WITH INCREASED EFFICACY OF MICVOTABART PELIDOTIN (MICVO) DUE TO GREATER LINKER CLEAVAGE WERE IDENTIFIED BASED ON DIFFERENTIAL GENE EXPRESSION ANALYSIS OF PDX RESPONDERS/NON-RESPONDERS

PYXIS ONCOLOGY PRESENTS PROMISING PRECLINICAL RESULTS PROVIDING PROOF OF MECHANISM OF MICVOTABART PELIDOTIN, THE FIRST-IN-CONCEPT EXTRACELLULAR-TARGETING ADC

BOSTON, APRIL 02, 2025 (GLOBE NEWSWIRE) -- PYXIS ONCOLOGY, INC. (NASDAQ: PYXS), A CLINICAL-STAGE COMPANY DEVELOPING NEXT-GENERATION THERAPEUTICS FOR DIFFICULT-TO-TREAT CANCERS, TODAY ANNOUNCED THAT LARA S. SULLIVAN, M.D., PRESIDENT, CHIEF EXECUTIVE OFFICER AND CHIEF MEDICAL OFFICER, WILL PARTICIPATE IN A FIRESIDE CHAT AT THE STIFEL 2025 VIRTUAL TARGETED ONCOLOGY FORUM ON WEDNESDAY, APRIL 9, 2025, AT 11:30 A.M. ET. THE COMPANY WILL ALSO BE HOLDING ONE-ON-ONE INVESTOR MEETINGS AT THE EVENT.

PYXIS ONCOLOGY TO PARTICIPATE IN THE STIFEL 2025 VIRTUAL TARGETED ONCOLOGY FORUM

EXPRESSION DATA FROM PATIENT-DERIVED XENOGRAFT (PDX) MOUSE MODELS EXPOSED TO MICVOTABART PELIDOTIN (MICVO) INDICATE GENE SIGNATURES ASSOCIATED WITH EFFICACY, DEEPENING UNDERSTANDING OF MOA AND POTENTIAL PATIENT RESPONSE

PYXIS ONCOLOGY TO PRESENT NEW PRECLINICAL DATA SUPPORTING DEVELOPMENT OF FIRST-IN-CONCEPT ADC TARGETING EDB+FN IN TUMOR MICROENVIRONMENT AT AACR 2025

- RECENTLY REPORTED POSITIVE PRELIMINARY DATA FROM PHASE 1 DOSE ESCALATION TRIAL OF MICVOTABART PELIDOTIN (MICVO, FORMERLY PYX-201), INCLUDING A CONFIRMED 50% OBJECTIVE RESPONSE RATE BY RECIST 1.1 IN RECURRENT AND METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA (R/M HNSCC) - RECEIVED FAST TRACK DESIGNATION FROM THE U.S. FOOD AND DRUG ADMINISTRATION FOR MICVO FOR THE TREATMENT OF ADULT PATIENTS WITH R/M HNSCC WHOSE DISEASE HAS PROGRESSED FOLLOWING TREATMENT WITH PLATINUM-BASED CHEMOTHERAPY AND AN ANTI-PD-(L)1 THERAPY - INITIATED MONOTHERAPY EXPANSION COHORTS OF MICVO FOR 2L AND 3L R/M HNSCC PATIENTS WHO HAVE RECEIVED PRIOR PLATINUM-BASED CHEMOTHERAPY AND PRIOR PD-(L)1 INHIBITOR THERAPY WITH PRELIMINARY DATA EXPECTED IN 2H25 AND 2/3L R/M HNSCC PATIENTS WHO HAVE RECEIVED PRIOR EGFRI AND PD-1 INHIBITOR THERAPY WITH PRELIMINARY DATA EXPECTED 1H26 -INITIATED MICVO IN COMBINATION WITH MERCK'S ANTI-PD-1 THERAPY, KEYTRUDA (PEMBROLIZUMAB), IN 1/2L+ R/M HNSCC PATIENTS AS PART OF A RECENTLY ANNOUNCED CLINICAL TRIAL COLLABORATION AGREEMENT WITH MERCK (KNOWN AS MSD OUTSIDE OF THE US AND CANADA) WITH PRELIMINARY DATA EXPECTED IN 2H25 - STREAMLINED ORGANIZATION AND IMPLEMENTED OPERATIONAL INITIATIVES TO FOCUS RESOURCES ON THE EXECUTION OF THE MICVO CLINICAL PROGRAM, INCLUDING WORKFORCE REDUCTION OF APPROXIMATELY 20% - EXPECTED CASH RUNWAY INTO 2H26 BOSTON, MARCH 18, 2025 (GLOBE NEWSWIRE) -- PYXIS ONCOLOGY, INC. (NASDAQ: PYXS), A CLINICAL-STAGE COMPANY DEVELOPING NEXT-GENERATION THERAPEUTICS FOR DIFFICULT-TO-TREAT CANCERS, TODAY REPORTED FINANCIAL RESULTS FOR THE YEAR AND QUARTER ENDED DECEMBER 31, 2024, AND PROVIDED A BUSINESS UPDATE. WE ARE COMMITTED TO THE DEVELOPMENT OF A NOVEL THERAPY FOR PATIENTS WITH RECURRENT OR METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA WHO WILL PROGRESS FOLLOWING PLATINUM-BASED THERAPIES AND PRIOR PD-(L)1 THERAPY, AND THOSE THAT PROGRESS AFTER CURRENT AND EMERGING EGFRI THERAPIES, SAID LARA S.

PYXIS ONCOLOGY REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BOSTON, MARCH 03, 2025 (GLOBE NEWSWIRE) -- PYXIS ONCOLOGY, INC. (NASDAQ: PYXS), A CLINICAL-STAGE COMPANY DEVELOPING NEXT-GENERATION THERAPEUTICS FOR DIFFICULT-TO-TREAT CANCERS, TODAY ANNOUNCED THAT LARA S. SULLIVAN, M.D.

PYXIS ONCOLOGY TO PARTICIPATE AT THE LEERINK PARTNERS GLOBAL HEALTHCARE CONFERENCE

DESIGNATION APPLIES TO THE TREATMENT OF ADULT PATIENTS WITH RECURRENT OR METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA (R/M HNSCC) WHOSE DISEASE HAS PROGRESSED FOLLOWING TREATMENT WITH PLATINUM-BASED CHEMOTHERAPY AND AN ANTI-PD-(L)1 ANTIBODY DESIGNATION APPLIES TO THE TREATMENT OF ADULT PATIENTS WITH RECURRENT OR METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA (R/M HNSCC) WHOSE DISEASE HAS PROGRESSED FOLLOWING TREATMENT WITH PLATINUM-BASED CHEMOTHERAPY AND AN ANTI-PD-(L)1 ANTIBODY

PYXIS ONCOLOGY GRANTED FDA FAST TRACK DESIGNATION FOR PYX-201 MONOTHERAPY IN PATIENTS WITH RECURRENT OR METASTATIC HEAD AND NECK CANCER

- INITIATION OF PHASE 1/2 COMBINATION TRIAL WITH PYX-201, AN EXTRACELLULAR ADC TARGETING EXTRADOMAIN-B FIBRONECTIN (EDB+FN) AND MERCK'S KEYTRUDA (PEMBROLIZUMAB) IN MULTIPLE SOLID TUMORS

Pyxis Oncology, Inc.

PYXS

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Pyxis Oncology, Inc.

PYXS.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

PYXS